RISANKIZUMAB
risankizumab 150 mg/mL injection, 1 mL pen device
RISANKIZUMAB (14732J)
14732J
Manner of administration:Injection
Restriction
Indication: Severe psoriatic arthritis
Treatment phase: Initial treatment - Initial 1 (new patient)
Restriction
Indication: Severe psoriatic arthritis
Treatment phase: Initial treatment - Initial 2 (change or recommencement of treatment after a break
in biological medicine of less than 5 years)
Restriction
Indication: Severe psoriatic arthritis
Treatment phase: Initial treatment - Initial 3 (recommencement of treatment after a break in biological
medicine of more than 5 years)
Restriction
Indication: Severe psoriatic arthritis
Treatment phase: Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after
a break in biological medicine of less than 5 years) or Initial 3 (recommencement
of treatment after a break in biological medicine of more than 5 years) - balance
of supply
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 1 | # of repeats: 2 | DPMQ: $5,140.26 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Skyrizi | |||||